Pentixapharm Receives FDA Guidance for Phase 3 PANDA Study of 68Ga-PentixaFor in Primary Aldosteronism
Key Insights
Pentixapharm received encouraging feedback from the FDA during a Type B pre-IND meeting for its planned Phase 3 PANDA study of 68Ga-PentixaFor in treatment-resistant hypertension (search) and primary aldosteronism (search).
The radiodiagnostic candidate targets CXCR4 (search) using PET/CT imaging and has demonstrated clinical experience in approximately 1,600 patients across different indications.
Primary aldosteronism (search) remains widely underdiagnosed despite its substantial clinical impact, representing a significant unmet medical need for earlier and more accurate detection.
Pentixapharm Holding AG (search) has received encouraging feedback from the U.S. Food and Drug Administration during a Type B pre-IND meeting regarding its planned Phase 3 PANDA study of [68Ga]Ga-PentixaFor, a CXCR4 (search)-directed radiodiagnostic intended to improve the diagnostic pathway for patients with treatment-resistant hypertension (search) and primary aldosteronism (search). The clinical-stage biotech company is developing first-in-class radiopharmaceuticals to address what remains a widely underdiagnosed condition with substantial clinical and societal impact.
FDA Meeting Provides Strategic Guidance
During the meeting, the FDA provided initial, non-binding feedback on key components of Pentixapharm's draft Phase 3 clinical protocol, including proposed inclusion criteria and design as well as statistical parameters. The FDA's input is considered essential for the Phase 3 study to meet effectiveness requirements and shape the final Investigational New Drug submission.
"We appreciate the constructive dialogue with the FDA and the opportunity to align on technical details and clarify outstanding questions," said Dr. Dirk Pleimes, CEO and CMO of Pentixapharm. "The preliminary feedback supports our plan to advance [68Ga]Ga-PentixaFor into Phase 3 and provides an important step toward bringing a potentially scalable and non-invasive diagnostic tool to patients with primary aldosteronism (search) who currently lack reliable, non-invasive options."
Addressing Diagnostic Challenges in Primary Aldosteronism
[68Ga]Ga-PentixaFor is a novel gallium-68 (search)-labeled radiodiagnostic designed to selectively target and visualize the chemokine receptor CXCR4 (search) using high-resolution PET/CT imaging. Clinical experience with the candidate in approximately 1,600 patients across different indications has demonstrated its ability to non-invasively image CXCR4 expression in vivo.
Recent research has shown strong CXCR4 (search) overexpression in aldosterone-producing adrenal tumors, a hallmark of unilateral primary aldosteronism (search). Primary aldosteronism is a common but historically underdiagnosed cause of secondary hypertension (search), largely because reliably distinguishing unilateral from bilateral disease remains challenging with current diagnostic tools.
The distinction between unilateral and bilateral disease is clinically critical, as unilateral disease is typically treated by surgical removal of the affected adrenal gland whereas bilateral disease requires life-long medical therapy. By visualizing CXCR4 (search) expression in aldosterone-producing tissue, [68Ga]Ga-PentixaFor has the potential to support more reliable subtyping of primary aldosteronism (search) and thereby better guide appropriate treatment decisions.
Next Steps and Regulatory Strategy
Pentixapharm expects to receive formal FDA meeting minutes that will inform refinements to the Phase 3 study design. The company plans to continue updating the market as it progresses along its IND strategy. Further details on the Phase 3 clinical setup are expected upon receipt of the FDA's official meeting minutes.
The development aligns with Pentixapharm's broader strategy to advance precision diagnostics in oncology and cardiology. The Berlin-based company's clinical pipeline is anchored by CXCR4 (search)-targeted PET-CT programs, with the primary aldosteronism (search) diagnostic representing a Phase 3-ready candidate intended to enable targeted treatment of underlying causes of hypertension.